How does the Timing of Chemotherapy Affect Outcome Following Radical Surgery for Malignant Pleural Mesothelioma?

Highlights • Giving chemotherapy as part of multimodality therapy has been shown to improve survival. • No effect of the timing of chemotherapy on survival in this retrospective analysis. • The only improved survival was in subgroup analyses. • In patients with non-epithelioid disease, adjuvant chem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-10, Vol.100, p.5-13
Hauptverfasser:	Sharkey, Annabel J., MBChB, O’Byrne, Kenneth J., MBChB, MD, Nakas, Apostolos, MD, Tenconi, Sara, Fennell, Dean A., MBBS, PhD, Waller, David A., BMedSci, BM, BS
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Chemotherapy Chemotherapy, Adjuvant Combined Modality Therapy - methods Disease Progression Disease-Free Survival Female Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lung Neoplasms - surgery Lymphatic Metastasis Male Mesothelioma Mesothelioma - drug therapy Mesothelioma - pathology Mesothelioma - surgery Mesothelioma, Malignant Middle Aged Multimodality therapy Neoplasm Staging Pleural Neoplasms - drug therapy Pleural Neoplasms - pathology Pleural Neoplasms - surgery Pneumonectomy - methods Pulmonary/Respiratory Radiotherapy, Adjuvant Retrospective Studies Survival Thoracic Surgical Procedures - methods Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Giving chemotherapy as part of multimodality therapy has been shown to improve survival. • No effect of the timing of chemotherapy on survival in this retrospective analysis. • The only improved survival was in subgroup analyses. • In patients with non-epithelioid disease, adjuvant chemotherapy improved survival. • In those with nodal disease adjuvant chemotherapy improved progression free survival
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2016.07.023